The rise of genomic profiling in ovarian cancer.
Next-generation sequencing and advances in 'omics technology have rapidly increased our understanding of the molecular landscape of epithelial ovarian cancers. Areas covered: Once characterized only by histologic appearance and clinical behavior, we now understand many of the molecular phenotypes that underlie the different ovarian cancer subtypes. While the current approach to treatment involves standard cytotoxic therapies after cytoreductive surgery for all ovarian cancers regardless of histologic or molecular characteristics, focus has shifted beyond a 'one size fits all' approach to ovarian cancer. Expert commentary: Genomic profiling offers potentially 'actionable' opportunities for development of targeted therapies and a more individualized approach to treatment with concomitant improved outcomes and decreased toxicity.
a Department of Gynecologic Oncology and Reproductive Medicine , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Rebecca A
RA
Previs
a Department of Gynecologic Oncology and Reproductive Medicine , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Anil K
AK
Sood
b Department of Systems Biology , The University of Texas MD Anderson Cancer , Houston , TX , USA.
Gordon B
GB
Mills
a Department of Gynecologic Oncology and Reproductive Medicine , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Shannon N
SN
Westin
D014408:Biomarkers, Tumor; D000077216:Carcinoma, Ovarian Epithelial; D002986:Clinical Trials as Topic; D005260:Female; D018740:Genetic Heterogeneity; D014644:Genetic Variation; D023281:Genomics / Q000379:methods; D059014:High-Throughput Nucleotide Sequencing; D006801:Humans; D058990:Molecular Targeted Therapy; D009154:Mutation; D009375:Neoplasms, Glandular and Epithelial / Q000175:diagnosis / Q000235:genetics; D010051:Ovarian Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics* / Q000378:metabolism; D000067856:Poly(ADP-ribose) Polymerase Inhibitors / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D057285:Precision Medicine / Q000379:methods; D011379:Prognosis; D015398:Signal Transduction / Q000187:drug effects; D016896:Treatment Outcome
D014408:Biomarkers, Tumor; D000067856:Poly(ADP-ribose) Polymerase Inhibitors
Genomic profiling; ovarian cancer; precision medicine; targeted therapy